Atlas Trials

Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

Clinical trial NCT04560790 · COMPLETED

Trial details

NCT number
NCT04560790
Sponsor
Shanghai BDgene Co., Ltd.
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Viral KeratitisBlindness EyeHerpes Simplex Virus InfectionCornea
Start date
2020-11-04
Primary completion
2022-07-05
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.